Cancer Prevention Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.canprevent.com
Clinical Trials
9
Active:5
Completed:2
Trial Phases
3 Phases
Phase 1:5
Phase 2:1
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 3
3 (33.3%)Phase 2
1 (11.1%)Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Phase 2
Withdrawn
- Conditions
- Focus of Study: Drug Response Biomarkers, Chemoprevention, Neoplasms
- Interventions
- Drug: difluoromethylornithine
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Registration Number
- NCT01636128
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase 3
Completed
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT01483144
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Phase 3
Withdrawn
- Conditions
- Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Registration Number
- NCT01245816
News
No news found